Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatment
Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now.
With a first-in-class nod, the FDA has cleared Yesc...
Continue Reading →
